When the platform and the pharmacy are the same business, a state action against one is an action against your prescription.
Washington State took action against Aequita, the Kirkland compounding pharmacy operated by Mochi Health, as reported in provider reviews published in April 2026. Mochi is one of the larger compounded GLP-1 telehealth platforms and dispenses through a pharmacy it owns.
That vertical structure is the part worth understanding. Most telehealth programs coordinate care and send prescriptions to third-party 503A pharmacies; a handful own the pharmacy. Ownership is not a problem in itself — it can mean tighter control of the supply chain — but it removes a layer of independent oversight, and a regulatory action against the pharmacy lands directly on patients of the platform with no alternative fulfilment route.
Ask any program whether it owns its dispensing pharmacy or contracts with one, and if it contracts, with how many. A program with several named partners can reroute a prescription when one facility has a problem. A program with one owned facility cannot.
We have not independently verified the state action and Mochi continues to appear in our tables with its verified $278 all-in price. This is recorded because it is the kind of structural fact that no pricing table shows and that matters most at exactly the moment something goes wrong.
Sources
- Washington State action against Aequita, as reported in named provider reviews, April 2026
- Mochi Health published pricing, verified 2026-08-05
Dated 2026-04-15. If this item is out of date or wrong, tell us through contact and the change is logged in corrections.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.